Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
Once complete, the site will serve as AbbVie’s U.S. center of excellence for SVP manufacturing
While many cases are treatable, a subset can become highly aggressive, spreading to distant organs and resisting conventional therapies
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
The newly formed team is led by Tomabu Adjobimey, an immunologist known for his work in host-pathogen interactions and immune modulation
The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
The presentations underscore the company’s deep expertise in dermatology and immunology
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
